Navigation Links
ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
Date:10/31/2007

SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, ADVENTRX's chief executive officer, is scheduled to present at the 18th Annual CIBC Healthcare Conference on November 5th, 2007 at 10:20 a.m. Eastern Time. The conference takes place in New York at the Waldorf Astoria hotel, November 5 - 7, 2007.

The presentation will be webcast live via the "Investors" section of the Company's web site at http://www.adventrx.com under "Events." The webcast will be available for replay for 14 days and can be accessed through the same link.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the ability to timely enroll subjects in and the results of ADVENTRX's current and anticipated clinical trials; the potential for ADVENTRX's product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; the market potential for ADVENTRX's product candidates and ADVENTRX's ability to compete in those markets; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Caloifornia (PRWEB) , ... December 07, 2016 , ... ... present the fifth annual Business Architecture Innovation Summit in Reston, VA on March ... world who will share a range of experiences from a cross-section of industries ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
(Date:12/6/2016)... ... December 06, 2016 , ... According to a November 1 ... consuming too many mints or not drinking enough water, which can cause bad breath ... Care notes that good oral hygiene not only helps reduce the possibility of bad ...
(Date:12/6/2016)... , ... December 06, 2016 , ... Mount Sinai Health ... the Department of Neurosurgery, where clinicians can confer and order 3D models for their ... low-cost fee-for-service basis with quick turnaround times. This resource will be the first ...
(Date:12/6/2016)... , ... December 06, 2016 , ... CarriersEdge, providers of ... a new suite of Driver Wellness courses. Offered in three modules, the courses can ... point so fleets can educate drivers about how to stay healthy on the road. ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
(Date:12/6/2016)... -- The pen needles market is projected to reach ... in 2016, growing at a CAGR of 11.2% during ... the years, the pen needles market has witnessed various ... demand for safety injections in the healthcare industry. These ... needles with an aim to reduce pain, increase comfort, ...
(Date:12/6/2016)... -- BTL Aesthetics today announced the release of a ... device was effectively redesigned for more efficient, predictable ... The result: Significantly better outcomes in abdominal fat ... versus BTL Vanquish. "We are committed ... with the most highly-advanced devices on the market," ...
Breaking Medicine Technology: